The effect of statins on survival in patients with stage IV lung cancer.

[1]  R. Hopkins,et al.  The Mevalonate Pathway and Innate Immune Hyper-Responsiveness in the Pathogenesis of COPD and Lung Cancer: Potential for Chemoprevention. , 2017, Current molecular pharmacology.

[2]  L. Murray,et al.  Statin Use and Survival from Lung Cancer: A Population-Based Cohort Study , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[3]  Bechien U. Wu,et al.  The Association of Statin Use after Cancer Diagnosis with Survival in Pancreatic Cancer Patients: A SEER-Medicare Analysis , 2015, PloS one.

[4]  A. Altwairgi.  Statins are potential anticancerous agents (review). , 2015, Oncology reports.

[5]  K. Yoon,et al.  Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with the T790M mutation of EGFR. , 2014, Experimental cell research.

[6]  A. Rosato,et al.  Metabolic control of YAP and TAZ by the mevalonate pathway , 2014, Nature Cell Biology.

[7]  Xiaofeng Yu,et al.  Simvastatin inhibits proliferation and induces apoptosis in human lung cancer cells. , 2013, Oncology research.

[8]  Y. Liang,et al.  Preclinical Activity of Simvastatin Induces Cell Cycle Arrest in G1 via Blockade of Cyclin D-Cdk4 Expression in Non-Small Cell Lung Cancer (NSCLC) , 2013, International journal of molecular sciences.

[9]  Lewis C Cantley,et al.  Inhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogen‐activated protein Kinase (MAPK) and Phosphatidylinositol‐3‐kinase (PI3K)/AKT pathways , 2012, Journal of cellular physiology.

[10]  J. Meyerhardt,et al.  Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. , 2011, Journal of the National Cancer Institute.

[11]  E. Halm,et al.  Survival and risk of adverse events in older patients receiving postoperative adjuvant chemotherapy for resected stages II-IIIA lung cancer: observational cohort study , 2011, BMJ : British Medical Journal.

[12]  Heung Tae Kim,et al.  A Randomized Phase II Study of Gefitinib Plus Simvastatin Versus Gefitinib Alone in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer , 2011, Clinical Cancer Research.

[13]  Kevin J. Anstrom,et al.  Using Inverse Probability-Weighted Estimators in Comparative Effectiveness Analyses With Observational Databases , 2007, Medical care.

[14]  C. Klabunde,et al.  A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. , 2007, Annals of epidemiology.

[15]  C. Klabunde,et al.  Data Sources for Measuring Comorbidity: A Comparison of Hospital Records and Medicare Claims for Cancer Patients , 2006, Medical care.

[16]  M. Cheang,et al.  Validity of a Prescription Claims Database to Estimate Medication Adherence in Older Persons , 2006, Medical care.

[17]  J. Quigley,et al.  Matrix metalloproteinases and tumor metastasis , 2006, Cancer and Metastasis Reviews.

[18]  J. Kluger,et al.  Statins and cancer risk: a meta-analysis. , 2006, JAMA.

[19]  Deborah Schrag,et al.  Overview of the SEER-Medicare Data: Content, Research Applications, and Generalizability to the United States Elderly Population , 2002, Medical care.

[20]  Beth A Virnig,et al.  Utility of the SEER-Medicare Data to Identify Chemotherapy Use , 2002, Medical care.

[21]  M. Minden,et al.  HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis , 2002, Leukemia.

[22]  J L Warren,et al.  Development of a comorbidity index using physician claims data. , 2000, Journal of clinical epidemiology.

[23]  Shigeyoshi Itohara,et al.  Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.

[24]  R. Deyo,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.

[25]  C. Muir,et al.  International Classification of Diseases for Oncology , 1990 .

[26]  E. Kopel,et al.  Statin use and reduced cancer-related mortality. , 2013, The New England journal of medicine.

[27]  C Michael White,et al.  Statins and Cancer Risk: A Meta-analysis , 2007 .

[28]  Kelvin K. W. Chan,et al.  The statins as anticancer agents. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  L. J. Wei,et al.  Regression analysis of multivariate incomplete failure time data by modeling marginal distributions , 1989 .

[30]  D. Ettinger,et al.  Clinical Epidemiology Dovepress Survival by Histologic Subtype in Stage Iv Nonsmall Cell Lung Cancer Based on Data from the Surveillance, Epidemiology and End Results Program , 2022 .